EUVIMED · CrossrefZeitschrift
Antibody Therapeutics
ISSN 2516-4236 · Oxford University Press (OUP)
Neueste Artikel
Potent Antitumor Efficacy of a Novel ALPPL2/ALPP-Targeting Antibody-Drug Conjugate in Preclinical Models
Engineering a novel asymmetric head-to-tail (HtT) 1+1 and 2+1 T cell bispecific antibody (TCB) platform with superior T cell killing compared to 1+1 bispecific IgG antibodies
Hetero-hexamerization as a means to improve broadly neutralizing antibody activity against HIV-1
The barrier effect of high-affinity IgM neutralizing antibodies provides enhanced blockage against rabies virus transport and infection
PPBind-3D/1D: protein–protein binding affinity prediction for structural and sequence data
Experimentally anchored, MHC-agnostic prediction of immunogenicity and cytokine release
Beyond affinity: AI-supported developability assessment and multi-objective optimization in antibody development
Ultrahigh-DAR antibody–drug conjugates: advancing the next generation of targeted therapy
Dual-component CAR T cell therapy: targeting BCMA with convertible CAR and MicAbodies
Generation and characterization of a CEACAM5 × CDH17 × CD3 tri-specific T-cell engager for colorectal cancer therapy
Profiling the efficacy of CR1 monoclonal antibody series against New World Arenaviruses
Developability improvement of an MMP-9 inhibitory mAb by CDR-H3 hydrophobic residue substitution
Mass photometry reveals stoichiometry and binding dynamics of bispecific tetravalent anti-VEGF–PD-1 antibody ivonescimab
Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics
Ivonescimab and other anti-programmed death-1/ligand 1 (PD-(L)1)/vascular endothelial growth factor (VEGF) bispecific antibodies: progress and prospects in cancer therapy
IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy
Integrative and Emerging Models in Antibody Research: A Comprehensive Review
CAR NK cell therapy for solid tumors: potential and challenges
Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase
Assessing the therapeutic potential of a panel of novel VCAM-1 antibodies using microfluidic and three-dimensional in vitro models of vascular inflammation
Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors
Fundamental properties and principal areas of focus in antibody–drug conjugates formulation development
Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate
Practical advice in the development of a lyophilized protein drug product
Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research
Connexin 43 hemichannels and related diseases
Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies
Challenges and solutions for the downstream purification of therapeutic proteins
Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics
Role of harvest depth filtration in controlling product-related impurities for a bispecific antibody
EUVIMED